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Abstract
Background: Melioidosis is an important cause of morbidity and mortality in East Asia. Recurrent melioidosis occurs in
around 10% of patients following treatment either because of relapse with the same strain or re-infection with a new strain
of Burkholderia pseudomallei. Distinguishing between the two is important but requires bacterial genotyping. The aim of
this study was to develop a simple scoring system to distinguish re-infection from relapse.
Methods: In a prospective study of 2,804 consecutive adult patients with melioidosis presenting to Sappasithiprasong
Hospital, NE Thailand, between1986 and 2005, there were 141 patients with recurrent melioidosis with paired strains
available for genotyping. Of these, 92 patients had relapse and 49 patients had re-infection. Variables associated with
relapse or re-infection were identified by multivariable logistic regression and used to develop a predictive model.
Performance of the scoring system was quantified with respect to discrimination (area under receiver operating
characteristic curves, AUC) and categorization (graphically). Bootstrap resampling was used to internally validate the
predictors and adjust for over-optimism.
Findings: Duration of oral antimicrobial treatment, interval between the primary episode and recurrence, season, and renal
function at recurrence were independent predictors of relapse or re-infection. A score of ,5 correctly identified relapse in
76 of 89 patients (85%), whereas a score $5 correctly identified re-infection in 36 of 52 patients (69%). The scoring index
had good discriminative power, with a bootstrap bias-corrected AUC of 0.80 (95%CI: 0.73–0.87).
Conclusions: A simple scoring index to predict the cause of recurrent melioidosis has been developed to provide important
bedside information where rapid bacterial genotyping is unavailable.
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Introduction
Melioidosis, a serious Gram-negative infection caused by
Burkholderia pseudomallei, is endemic across much of rural East and
South Asia and innorthern Australia [1]. The causative organism is
present in the environment in these areas and infection is acquired
by bacterial inoculation or inhalation. B. pseudomallei causes 20% of
community-acquired septicemias in northeast Thailand [2], and is
the most common cause of fatal community-acquired bacteremic
pneumonia in Darwin, Australia [3]. Acute melioidosis is treated
with parenteral treatment for at least 10 days, followed by oral
treatment for 20 weeks [1]. The overall mortality of acute
melioidosis is 50% in NE Thailand (35% in children), and 19%
in Australia [1,4]. Recurrent infection occurs despite 20 weeks of
antimicrobial treatment and is the most important complication in
survivors, affecting 13% of Thai patients who survive the primary
episode [5]. A study that compared the bacterial genotype of strain
pairs isolated during primary and recurrent melioidosis in over one
hundred patients demonstrated that three quarters of cases were
due to relapse (paired isolates had the same genotype), and one
quarter were due to re-infection with a new strain [6]. Clinically
this is an important distinction, with implications for epidemiology,
investigation and management, but the overwhelming majority of
medical centers treating patients with melioidosis in Asia do not
have the facilities to perform bacterial genotyping and recurrence is
usually considered to be synonymous with relapse. In addition,
isolates from the primary episode are usually unavailable because
bacterial strains are not routinely frozen. The purpose of this study
was to define the association of readily accessible factors with
relapse or re-infection, and to use these to develop a simple scoring
system to help distinguish the most probable cause of recurrent
melioidosis.
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Patients
Study patients were adults ($15 years) with culture-confirmed
recurrent melioidosis who presented to Sappasithiprasong Hospi-
tal, Ubon Ratchathani, northeast Thailand between June 1986
and September 2005 and who were included in prospective studies
of antimicrobial chemotherapy during this period. The standard of
care throughout the study period was inpatient intravenous
antimicrobial therapy, followed by a prolonged course of oral
drugs. The prospective studies were either trials comparing
parenteral antimicrobial regimens or trials comparing oral
eradicative treatment regimens, as previously described (see [7]
for list of published trials). Patients were followed up for recurrent
melioidosis as a secondary outcome for trials comparing parenteral
drugs and as a primary outcome for trials comparing oral
treatment regimens.
Patients with suspected melioidosis were identified by twice-
daily active case finding in the medical and intensive care wards.
As part of eligibility screening for the clinical trials a history and
examination was performed and samples taken for culture from
suspected cases (blood culture, throat swab, respiratory secretions,
pus or surface swab from wounds and skin lesions). Microbiology
specimens were cultured for the presence of B. pseudomallei,a s
described previously [8]. Additional passive surveillance was
undertaken via the diagnostic microbiology laboratory for patients
on the surgical and pediatric wards with cultures positive for B.
pseudomallei. All isolates were stored in trypticase soy broth with
15% glycerol at 280uC. A history and full clinical examination
was performed on all cases of culture proven melioidosis. Details of
history, examination, laboratory results, antimicrobial treatment
and clinical course were maintained on a password protected
computer database. Patients who survived the primary episode
received oral eradicative treatment and were followed up monthly
for one year, then yearly thereafter. Oral antimicrobial regimens
were as described elsewhere [7]. Patients with recurrence were
identified from the history, patient notes and by cross-reference
with our database. Follow up data in this study was to February
2007. Ethical permission for all clinical trials was obtained from
the Ethical and Scientific Review Subcommittee of Thai Ministry
of Public Health. Patients gave written informed consent to
participate in the trials.
Genotyping and definition of relapse and re-infection
Single isolates obtained from the first and recurrent episode
were compared using a combination of PFGE and MLST, as
described previously [6,9]. Recurrent melioidosis was defined as
the development of new symptoms and signs of infection in
association with a culture positive for B. pseudomallei following
initial response to oral antibiotic therapy. Relapse and re-infection
were defined on the basis of typing of isolates from the first and
subsequent episode(s). Isolates from the same patient with an
identical banding pattern on PFGE were considered to represent a
single strain and these patients were classified as having relapse.
Isolates from the same patient that differed by one or more bands
were examined using a screening approach based on MLST, as
described previously [6]. Isolates from the same patient with a
different sequence type (ST) were classified as representing re-
infection, while those with an identical ST were classified as
representing relapse.
Antimicrobial susceptibility testing
All B. pseudomallei isolates were tested for susceptibility to the
antimicrobial drugs used to treat melioidosis (meropenem, ceftazi-
dime,amoxicillin-clavulanicacid,chloramphenicol,doxycycline and
trimethoprim/sulfamethoxazole (TMP-SMX)). This was performed
using the disk diffusion method with the exception of TMP-SMX,
which was assessed using the Etest (AB Biodisk, Solna, Sweden) [10].
Allisolatesdefinedasintermediateorresistanttoagivendrugbydisk
diffusionweretestedfurtherusingtheE-test.Interpretativestandards
werebased on CLSIguidelines,whichlistsresistance forceftazidime,
amoxicillin-clavulanic acid, doxycycline and TMP-SMX as
$32 mg/L,$32 mg/L,$16 mg/land$4/76 mg/L, respectively,
and intermediate resistance as 16 mg/L, 16 mg/L, 8 mg/l and N/
A, respectively [11].
Definitions
Diabetes mellitus was defined as either pre-existing, or a new
diagnosis as defined by the American Diabetes Association criteria
[12]. Impaired renal function was defined as an estimated
glomerular filtration rate (GFR) below 60 mL/min/1.73 m
2 at
admission. GFR was estimated using an abbreviated form of the
Modification of Diet in Renal Disease study equation [13].
Hypotension was defined as a systolic blood pressure less than
90 mmHg, acute renal failure as a 50% decrease in the baseline-
calculated GFR [14], and respiratory failure as the need for
mechanical ventilation. The time between the primary episode
and recurrent episode was measured from the start of oral
antimicrobial therapy to the clinical onset of culture-confirmed
recurrent infection.
Statistical analysis
The primary outcome of interest was cause of recurrent
infection. Comparison between relapse and re-infection for each
variable was performed using Fisher’s exact test or the Wilcoxon-
Mann-Whitney test, as appropriate. We selected potential
Author Summary
Melioidosis is a serious infectious disease caused by the
Gram-negative bacterium, Burkholderia pseudomallei. This
organism is present in the environment in areas where
melioidosis is endemic (most notably East Asia and
Northern Australia), and infection is acquired following
bacterial inoculation or inhalation. Despite prolonged oral
eradicative treatment, recurrent melioidosis occurs in
approximately 10% of survivors of acute melioidosis.
Recurrent melioidosis can be caused by relapse (failure
of initial eradicative treatment) or re-infection with a new
infection. The aim of this study was to develop a simple
scoring system to distinguish between re-infection and
relapse, since this has implications for antimicrobial
treatment of the recurrent episode, but telling the two
apart normally requires bacterial genotyping. A prospec-
tive study of melioidosis patients in NE Thailand conduct-
ed between 1986 and 2005 identified 141 patients with
recurrent melioidosis. Of these, 92 patients had relapse
and 49 patients had re-infection as confirmed by
genotyping techniques. We found that relapse was
associated with previous inadequate treatment and
shorter time to clinical features of recurrence, while re-
infection was associated with renal insufficiency and
presentation during the rainy season. A simple scoring
index to help distinguish between relapse and re-infection
was developed to provide important bedside information
where rapid bacterial genotyping is unavailable. Guidelines
are provided on how this scoring system could be
implemented.
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experience and information from other studies [5–7]. The
variables considered included sex, age, diabetes, estimated GFR
during recurrent infection, body sites involved in the primary and
recurrent episode, complications of recurrent infection, antimi-
crobial treatment given for the primary episode, patterns of
antimicrobial resistance for the primary and recurrent isolates,
calendar month of presentation of recurrent episode, and duration
between primary and recurrent episode. The creatinine level on
recurrent episode was missing for 17 patients (12%) and the most
recent creatinine levels during follow-up before the recurrent
episode were used instead.
Variables associated with relapse/re-infection at p,0.20 were
included as independent variables in a multivariable logistic
regression model with relapse/re-infection as the dependent
variable. Variables were removed one at a time from the model
if the p-value as determined by the likelihood ratio test was .0.05,
least significant variable first. To double check that no significantly
predictive variables were removed during this process, each de-
selected variable was tested in turn with the final model and
reintroduced into the model if p,0.05 [15].
Variables in the final model were used to construct a scoring
system. For simplicity, estimated GFR was categorized into four
levels (,30, 30 to ,60, 60 to ,90 or $90) based on clinical
practice guidelines [13]. Time to recurrent melioidosis was
dichotomized (,1 year or $1 year) and duration of oral treatment
received on primary episode was categorized into four levels (,8
weeks, 8 to ,16 weeks, 16 to 20 weeks or .20 weeks) based on
previous knowledge [6,7]. These dummy variables were used in a
multivariable logistic regression analysis. The coefficient for each
variable was multiplied by 10 and rounded off to the nearest
integer. A total score was calculated by summing the points from
each variable for each patient, and the results plotted on a
receiver-operator characteristic curve. The Hosmer-Lemeshow
goodness-of-fit test was used to evaluate the regression model.
Discrimination referred to the ability to distinguish re-infection
from relapse, and was quantified by the area under receiver
operating characteristic curves (AUC).
Bootstrap resampling procedures were used to assess the
internal validity of the model and to adjust for over-fitting or
over-optimism. The apparent performance of the scoring system
(AUC) on the original data set may be better than the performance
in another data set. One thousand random bootstrap samples were
drawn with replacement from the original data set. The logistic
regression model and scoring system generated from the bootstrap
sample was evaluated in the bootstrap sample and in the original
sample. The bootstrap sample set represented training data and
the original sample set represented test data. The difference
between the performances in both sets was an estimate of the
optimism in the apparent performance. This difference was
averaged to obtain a stable estimate of the optimism. The
optimism was subtracted from the apparent performance to
estimate the internally validated performance. All analyses were
performed using the statistical software STATA/SE version 9.0
(StataCorp LP, College Station, Tx.).
Results
A total of 2,804 adult patients with culture-confirmed
melioidosis were seen during the 19-year study period. Of these,
1,401 (50%) adult patients died during admission. Of the adults
who survived, 1,001 (71%) patients presented to follow up clinic at
least once. Median duration of follow-up for patients without
recurrence was 65 weeks (25
th percentile-75
th percentile, 22–179
weeks; range, 1–954 weeks). A total of 194 episodes of culture-
confirmed recurrent melioidosis occurred in 170 (17%) patients.
Of these, 148 (76%) strain pairs from the primary and recurrent
episode were available for genotyping from 141 patients. Bacterial
genotyping had been performed previously for 122 episodes in 115
patients [6], and genotyping of the remainder was performed
during this study.
Of the 148 episodes of recurrent melioidosis, 98 episodes in 92
(65%) patients were defined by genotyping as relapse. Four of
these patients relapsed twice and 1 patient relapsed three times.
The other 50 episodes in 49 (35%) patients were due to re-
infection. One patient had re-infection after completing treatment
for an episode of relapse. For the purposes of this study, only the
141 first episodes of recurrent melioidosis (92 relapse and 49 re-
infection) were analyzed.
All B. pseudomallei isolates associated with the primary episode of
recurrent infection were susceptible to ceftazidime, amoxicillin-
clavulanic acid and doxycycline, while 21/141 (15%) were
resistant to TMP-SMX. All isolates associated with recurrence
were susceptible to ceftazidime. Strains associated with re-infection
were resistant to amoxicillin-clavulanic acid, doxycycline and
TMP-SMX in 2% (1/49), 2% (1/49) and 16% (8/49) of cases,
respectively, while, strains associated with relapse were resistant in
1% (1/92), 1% (1/92) and 12% (11/92), respectively (p.0.05, all).
Two patients with relapse associated with the development of
bacterial resistance to amoxicillin-clavulanic acid (MIC from 2 to
16 mg/L) or doxycycline (MIC from 1 to 96 mg/L) received
antimicrobial treatment with the respective agent for at least 8
weeks prior to relapse.
The majority of patients with re-infection presented in the rainy
season, the period of greatest melioidosis incidence, while patients
with relapse presented throughout the calendar year without
evident seasonality (p=0.002, Figure 1A). Demographic charac-
teristics and clinical features are shown in Table 1. Sex and age
were comparable between the two groups. Diabetes mellitus was
the most common underlying condition in both relapse and re-
infection. Impaired renal function was present in 55 (60%) of 92
patients with relapse and 39 of 49 (80%) patients with re-infection
(p=0.02). Distribution of infection and organ involvement during
primary infection and at time of recurrence was not different
between patients with relapse and re-infection. There was no
difference in severity of infection between relapse and re-infection
as defined by hypotension, acute renal failure or respiratory failure
(p.0.05 in all cases). Death occurred in 17 (18%) patients with
relapse and 13 (27%) patients with re-infection (p=0.29).
On univariable analysis, the duration of oral antibiotic
treatment for the primary episode was significantly shorter for
patients with relapse than re-infection (p,0.001). The median
time to relapse was also significantly shorter than time to re-
infection (6 months versus 24 months, p,0.001) (Figure 1B). On
multivariable analysis, significant independent predictors of re-
infection were the presence of a low GFR on admission for the
recurrent episode, an interval between the primary infection, and
recurrence of more than one year and calendar period of
presentation (rainy season). Short duration of oral antimicrobial
treatment for first episode of infection was predictive for relapse
(Table 2). The AUC for this model was 0.81 (95% CI: 0.74–0.89),
and the Hosmer-Lemeshow goodness-of-fit test was not significant
for lack of fit (Hosmer-Lemeshow statistics=9.24, df=8,
p=0.32,).
A scoring system was generated based on a combination of
predictors of re-infection or relapse in the final logistic regression
model (Figure 2). Factors associated with re-infection (time to
recurrence more than one year, presentation during the rainy
A Predictive Index for Recurrent Melioidosis
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Factors associated with relapse were given a negative score. A non-
linear association was found between the duration of oral
treatment received and predictive value of relapse. A score was
reached based on the accumulation of points from the four
variables. The AUC for the re-infection score was 0.80 (95%CI:
0.73–0.87) after applying the bootstrap correction.
The predictive ability of the risk index model for relapse and re-
infection is depicted in Figure 3. A score of less than 5 correctly
identified relapse in 76 of 89 patients (85%) in this group, whereas
a score of more than or equal to 5 correctly identified re-infection
in 36 of 52 patients (69%).
Discussion
Determining the cause of recurrence in infectious diseases is
important as relapse and re-infection have different implications
for disease control and clinical management. Relapse reflects
treatment failure, in which antimicrobial regimen, elimination of a
persistent focus and drug adherence are the main concerns. This
contrasts with re-infection, which involves exogenous infection
with a new strain and therefore has implications for disease
prevention and health education strategies. In clinical practice,
cause and management of recurrent infection is highly complex
and standard second-line drug regimen may be recommended
where individualized retreatment schemes are not practical [16].
In recurrent melioidosis, if all recurrent episodes are assumed to be
relapse due to failure of primary eradicative treatment (TMP-
SMX based regimen), then inferior secondary treatment (amox-
ycillin-clavulanic acid) may be used despite the presence of an
organism that is still sensitive to TMP-SMX [17,18]. Use of
inferior second-line drugs would unnecessary expose patients with
re-infection to a higher risk of relapse from this new episode than
would otherwise be the case [7]. In addition, non-medical
treatment, the prevention of re-infection, remains ignored.
For many infectious diseases, the clinical differentiation of
relapse from re-infection is difficult or impossible, and genotyping
has generally been used for this purpose. Examples include
tuberculosis [19,20], malaria [21,22], Staphylococcus aureus bacter-
emia [23], pneumococcal bacteremia [24], infective endocarditis
[25] and nosocomial infections [26,27]. Two typing methods were
used in this study since MLST can resolve any uncertainty that
arises during the interpretation of DNA macrorestriction patterns
Figure 1. Comparison between patients with relapse and re-
infection in relation to: (A) calendar month of presentation and
(B) interval between primary episode and recurrent infection.
Dotted line in Figure 1B shows the proportion of patients with relapse
presenting within each interval (right Y axis).
doi:10.1371/journal.pntd.0000327.g001








Men, No. (%) 59 (64%) 29 (59%) 0.59
Age (yr) at recurrence, median (Q1–Q3) 49 (42–58) 47 (39–55) 0.25
Diabetes mellitus 58 (63%) 27 (55%) 0.37
Estimated GFR
* on admission with
recurrence, median (Q1–Q3)
53 (29–81) 40 (20–59) 0.02
Site(s) involved during recurrent infection
Bacteremia 43 (47%) 28 (57%) 0.29
Pneumonia 27 (29%) 17 (35%) 0.57
Liver abscess 17 (18%) 9 (18%) .0.99
Splenic abscess 14 (15%) 7 (14%) .0.99
Skin or soft tissue infection 31 (34%) 16 (33%) .0.99
Arthritis 13 (14%) 8 (16%) 0.81
Osteomyelitis 7 (8%) 1 (2%) 0.26
Complications of recurrent infection
Hypotension 15 (16%) 11 (22%) 0.37
Acute renal failure 22 (24%) 17 (35%) 0.24
Respiratory failure 10 (11%) 7 (14%) 0.59
First oral antibiotic regimen for primary episode
Three-drug regimen
{ 9 (10%) 6 (12%)
Four-drug regimen
{ 10 (11%) 12 (24%) 0.14
Amoxycillin-clavulanic acid 23 (25%) 12 (24%)
Other regimen
1 50 (54%) 19 (39%)
Duration of oral treatment for primary
episode, weeks, median (Q1–Q3)
1 (0–5) 16 (0–21) ,0.01
Recurrence in rainy season (June to
November)
44 (48%) 37 (76%) ,0.01
Time to recurrence (months) median
(Q1–Q3)
6 (2–17) 24 (9–45) ,0.01
Death attributable to recurrent melioidosis 17 (18%) 13 (27%) 0.29
Abbreviations: GFR, glomerular filtration rate; Q1–Q3, 25
th percentile and 75
th
percentile;




{ Trimethoprim-sulfamethoxazole, doxycycline, and
chloramphenicol,
1 Fluoroquinolone-based regimen, doxycycline alone, and
trimethoprim-sulfamethoxazole alone.
doi:10.1371/journal.pntd.0000327.t001
A Predictive Index for Recurrent Melioidosis
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confirm cluster assignments based on PFGE results in common
organisms [28–30]. However, genotyping techniques are not
widely available for tropical infections in endemic areas. In
addition, isolates are rarely stored outside of the research setting,
making it impossible to compare isolates associated with the
primary and recurrent infection.
Clinical differences between re-infection and relapse have been
proposed for Lyme disease, although a scoring system was not
developed [31]. Scoring systems have been described to predict
outcome from melioidosis [32], and to predict a number of other
events including atrial fibrillation after cardiac surgery [33]. To
our knowledge, our scoring system is the first clinically-based
scoring system to differentiate between relapse and re-infection in
any infectious disease. It is rapid and simple to use, necessitating
data on only four easy to assess factors. This scoring index can be
used where bacterial genotyping is unavailable, which covers
nearly all melioidosis-endemic regions. The factors associated with
recurrent melioidosis are similar to those reported for recurrence
of Lyme disease (relapse after previous inadequate treatment and
within a short period, and re-infection during the ‘high’ season
when ticks increase in numbers) [31], and may represent features
that could be used for assessing other infectious diseases.
Using genotyping to compare primary and recurrent isolates to
distinguish between relapse or re-infection could be confounded by
two major factors. First, ‘re-infection’ could actually represent
Table 2. Multivariable predictors of re-infection among
patients with recurrent melioidosis.
Predictor OR { (95% CI) P Value
Time to recurrent melioidosis more than one
year
3.33 (1.44–7.70) ,0.01
Presentation in rainy season (June to November) 3.11 (1.30–7.47) 0.01
Duration of oral treatment received
* 1.04 (1.01–1.08) 0.01
Estimated GFR on admission with recurrence




Abbreviations: CI, confidence interval; OR, odds ratio.
*The OR is for a week increase of treatment with effective oral treatment
regimens, including TMP-SMX and doxycycline based regimens and
amoxicillin-clavulanic acid regimen.
{The OR is for a 10 mL/min per 1.73 m
2 increase.
{Model Chi-square=42.10; df=4;P,0.001; area under ROC curve=0.81 (95%
CI: 0.74–0.89); Hosmer-Lemeshow statistics=9.24, df=8,P=0.32.
doi:10.1371/journal.pntd.0000327.t002
Figure 2. Four predictors of re-infection and relapse for patients with recurrent melioidosis. Points can be determined for each of the
predictors using the figure. Factors associated with re-infection give a positive score, while factors associated with relapse give a negative score. The
total score is reached by adding the points together for these four variables. A total score of more than or equal to 5 is predictive for re-infection as
the probable cause of recurrent melioidosis, while a total score of less than 5 is predictive for relapse.
doi:10.1371/journal.pntd.0000327.g002
A Predictive Index for Recurrent Melioidosis
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simultaneous infection with more than one bacterial strain, and
different strains were picked by chance for genotyping [34]. This is
unlikely in melioidosis since infection with more than one strain of
B. pseudomallei occurs in less than 2% of cases [35]. ‘Re-infection’
could also actually represent relapse if genetic events occurred in
vivo that led to alteration of one of the seven housekeeping genes
that are sequenced in order to generate a sequence type. This
would be predicted to be extremely unlikely as MLST is based on
the sequence of housekeeping genes which are under neutral
selection pressure [36]. Second, ‘relapse’ could actually represent
re-infection in the event that re-infection was caused by a different
strain that was nonetheless indistinguishable on genotyping from
the first infecting strain. This would happen when infection
sources were clonal or had limited genetic diversity, but this is
highly unlikely in melioidosis as the B. pseudomallei population in
the environment is extremely diverse [37].
Our finding of a non-linear association between duration of oral
treatment received for the primary episode and predictive value of
relapse is consistent with a previous analysis; patients treated for
more than 20 weeks may have included those with a slow response
to treatment or who had more complicated or severe disease
associated with a higher risk of treatment failure and relapse [7].
Bacteremia and multifocal infection during the primary episode
have been identified as risk factors for relapse compared to
patients who did not have relapse [7]; however, these two variables
were not significantly different between the relapse and re-
infection groups. B. pseudomallei isolates obtain from patients with
primary infection and re-infection were not resistant to amoxicil-
lin-clavulanic acid and doxycycline, a finding that is consistent
with previous studies [38,39]. Acquired antimicrobial resistance in
relapse organisms was also uncommon. A number of factors may
relate to this: acquired resistant to ceftazidime is infrequent and
related to fatal outcome during the acute episode of infection [40];
acquired resistance to carbapenems has never been observed in
our patients; and patients who had incomplete treatment with oral
eradicative drugs mainly abandoned their treatment due to drug
side effects, which may not increase the risk of selection of
resistance [1].
This scoring system will not affect prescribing practice relating
to the initial treatment of recurrent melioidosis; standard first-line
parenteral antimicrobials are recommended for the treatment of
both relapse and re-infection as acquired resistance to either
ceftazidime or carbapenems is uncommon. In general, first line
oral eradicative treatment (TMP-SMX) should be used if the
organism isolated is susceptible to this drug. However, the scoring
system could help to identify the cause of recurrent melioidosis and
may lead to individualized oral eradicative treatment and
management. Patients with recurrent infection require a detailed
history of initial treatment including duration of each drug used
and compliance, and any lifestyle modification made by the
patient that reduces exposure to environmental B. pseudomallei. For
patients with predicted re-infection, first-line eradicative treatment
should be used and education provided on prevention of further
re-infection. For patients with predicted relapse, efforts should be
focused on patient compliance and completion of a course of
therapy of adequate duration. The second-line, less effective
amoxycillin-clavulanic acid should be used in patients with relapse
only where in vivo failure of TMP-SMX is considered possible.
We propose that this scoring system can provide timely and
important bedside information where bacterial genotyping is
unavailable, though it would be important to validate it in different
settings, particularly those outside northeast Thailand.
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